| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fluorometholone Acetate (formerly NSC47438; NSC-47438; U 17,323; AI 3-52814; Flarex) is a synthetic corticosteroid that has been approved as a medication commonly used as eye drops in the treatment of steroid responsive inflammatory conditions of the eye.
| ln Vitro |
Lineweaver-Burk plots for fluorometholone acetate yield a Ki value of 1.044 μM (noncompetitive) for hCA-I and 9.98 μM (noncompetitive) for hCA-II[2].
|
||
|---|---|---|---|
| ln Vivo |
In New Zealand albino rabbits weighing 1.5–2.0 kg, an artificially induced inflammatory keratitis resulted in an average 47% reduction in the polymorphonuclear leukocytes invading the cornea when 0.1% fluorometholone acetate ophthalmic suspension was applied topically every hour. When given at three-hour intervals, 0.1% fluorometholone acetate, produced as a high-viscosity carbomer gel, reduced invading leukocytes in the cornea by an average of 48%; this impact was not statistically different from when the suspension was administered hourly[1].
|
||
| Animal Protocol |
|
||
| References |
[1]. A Kupferman, et al. Fluorometholone acetate. A new ophthalmic derivative of fluorometholone. Arch Ophthalmol. 1982 Apr;100(4):640-1.
[2]. Zuhal Alım, et al. Some Anti-Inflammatory Agents Inhibit Esterase Activities of Human Carbonic Anhydrase Isoforms I and II: An In Vitro Study. Chem Biol Drug Des. 2015 Oct;86(4):857-63. [3]. H M Leibowitz, et al. Fluoro metholone acetate: clinical evaluation in the treatment of external ocular inflammation. Ann Ophthalmol. 1984 Dec;16(12):1110-5. |
| Molecular Formula |
C24H31FO5
|
|
|---|---|---|
| Molecular Weight |
418.5
|
|
| CAS # |
3801-06-7
|
|
| Related CAS # |
|
|
| SMILES |
C[C@H]1C[C@H]2[C@@H]3CC[C@](C(=O)C)([C@@]3(C)C[C@@H]([C@@]2([C@@]4(C)C=CC(=O)C=C14)F)O)OC(=O)C
|
|
| InChi Key |
YRFXGQHBPBMFHW-SBTZIJSASA-N
|
|
| InChi Code |
1S/C24H31FO5/c1-13-10-19-17-7-9-23(14(2)26,30-15(3)27)22(17,5)12-20(29)24(19,25)21(4)8-6-16(28)11-18(13)21/h6,8,11,13,17,19-20,29H,7,9-10,12H2,1-5H3/t13-,17-,19-,20-,21-,22-,23-,24-/m0/s1
|
|
| Chemical Name |
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 17-acetate
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3895 mL | 11.9474 mL | 23.8949 mL | |
| 5 mM | 0.4779 mL | 2.3895 mL | 4.7790 mL | |
| 10 mM | 0.2389 mL | 1.1947 mL | 2.3895 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA